Evolent Health Stock EBITDA

EVH Stock

USD 22.81 0.15 0.65%

Evolent Health fundamentals help investors to digest information that contributes to Evolent Health's financial success or failures. It also enables traders to predict the movement of Evolent Stock. The fundamental analysis module provides a way to measure Evolent Health's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Evolent Health stock.

		Last Reported	Projected for Next Year
	EBITDA	46.4 M	48.7 M

The Evolent Health's current EBITDA is estimated to increase to about 48.7 M.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Evolent Health Company EBITDA Analysis

Evolent Health's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Evolent Health EBITDA

46.38 M

Most of Evolent Health's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Evolent Health is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Evolent EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Evolent Health is extremely important. It helps to project a fair market value of Evolent Stock properly, considering its historical fundamentals such as EBITDA. Since Evolent Health's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Evolent Health's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Evolent Health's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Current Deferred Revenue	Short Term Investments	Short Term Debt	Property Plant Equipment	Net Tangible Assets	Long Term Debt	Good Will	Deferred Long Term Liab	Long Term Investments	Common Stock	Capital Surpluse	Long Term Debt Total	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.86	0.76	-0.64	0.61	0.87	0.92	0.85	0.98	-0.48	0.24	-0.06	0.8	-0.57	0.82	0.45	-0.65	-0.27	0.92	0.85	0.76	-0.8	0.56	0.54	-0.8	0.76
Total Stockholder Equity	0.86		0.44	-0.32	0.74	0.52	0.62	0.84	0.74	-0.05	0.3	0.24	0.79	-0.25	0.48	0.35	-0.55	-0.15	0.94	0.79	0.61	-0.66	0.49	0.42	-0.55	0.45
Net Debt	0.76	0.44		-0.77	0.21	0.89	0.89	0.5	0.85	-0.69	-0.12	-0.57	0.64	-0.68	0.95	0.54	-0.56	0.0	0.58	0.7	0.83	-0.72	0.19	0.65	-0.9	0.86
Retained Earnings	-0.64	-0.32	-0.77		-0.27	-0.8	-0.85	-0.66	-0.7	0.77	-0.13	0.64	-0.77	0.5	-0.85	-0.16	0.77	0.23	-0.58	-0.81	-0.8	0.81	-0.59	-0.22	0.89	-0.81
Accounts Payable	0.61	0.74	0.21	-0.27		0.32	0.44	0.71	0.49	-0.01	0.31	0.22	0.65	-0.06	0.32	0.18	-0.22	-0.3	0.67	0.63	0.38	-0.66	0.54	0.23	-0.34	0.23
Net Receivables	0.87	0.52	0.89	-0.8	0.32		0.98	0.67	0.95	-0.77	0.12	-0.34	0.66	-0.72	0.96	0.57	-0.6	-0.36	0.67	0.75	0.79	-0.7	0.47	0.63	-0.84	0.94
Total Liab	0.92	0.62	0.89	-0.85	0.44	0.98		0.77	0.97	-0.71	0.14	-0.34	0.78	-0.66	0.96	0.47	-0.68	-0.3	0.77	0.84	0.83	-0.82	0.56	0.56	-0.89	0.9
Total Current Assets	0.85	0.84	0.5	-0.66	0.71	0.67	0.77		0.78	-0.36	0.32	-0.03	0.9	-0.36	0.63	0.29	-0.67	-0.43	0.93	0.92	0.75	-0.8	0.79	0.32	-0.65	0.65
Intangible Assets	0.98	0.74	0.85	-0.7	0.49	0.95	0.97	0.78		-0.59	0.18	-0.17	0.75	-0.66	0.91	0.55	-0.62	-0.3	0.83	0.81	0.79	-0.76	0.49	0.63	-0.83	0.86
Current Deferred Revenue	-0.48	-0.05	-0.69	0.77	-0.01	-0.77	-0.71	-0.36	-0.59		0.07	0.54	-0.38	0.81	-0.73	-0.36	0.36	0.3	-0.32	-0.47	-0.67	0.52	-0.25	-0.37	0.7	-0.84
Short Term Investments	0.24	0.3	-0.12	-0.13	0.31	0.12	0.14	0.32	0.18	0.07		0.29	0.18	0.04	-0.01	-0.17	-0.4	-0.45	0.33	0.23	-0.09	-0.02	0.37	-0.27	-0.1	0.08
Short Term Debt	-0.06	0.24	-0.57	0.64	0.22	-0.34	-0.34	-0.03	-0.17	0.54	0.29		-0.24	0.23	-0.46	-0.01	0.37	-0.19	0.02	-0.28	-0.42	0.36	-0.02	-0.06	0.54	-0.43
Property Plant Equipment	0.8	0.79	0.64	-0.77	0.65	0.66	0.78	0.9	0.75	-0.38	0.18	-0.24		-0.28	0.72	0.23	-0.78	-0.09	0.89	0.98	0.87	-0.92	0.64	0.32	-0.82	0.64
Net Tangible Assets	-0.57	-0.25	-0.68	0.5	-0.06	-0.72	-0.66	-0.36	-0.66	0.81	0.04	0.23	-0.28		-0.65	-0.53	0.18	0.36	-0.42	-0.39	-0.61	0.36	-0.04	-0.52	0.56	-0.78
Long Term Debt	0.82	0.48	0.95	-0.85	0.32	0.96	0.96	0.63	0.91	-0.73	-0.01	-0.46	0.72	-0.65		0.54	-0.61	-0.2	0.63	0.78	0.84	-0.78	0.41	0.64	-0.89	0.91
Good Will	0.45	0.35	0.54	-0.16	0.18	0.57	0.47	0.29	0.55	-0.36	-0.17	-0.01	0.23	-0.53	0.54		0.06	-0.21	0.27	0.32	0.53	-0.18	-0.11	0.97	-0.3	0.66
Deferred Long Term Liab	-0.65	-0.55	-0.56	0.77	-0.22	-0.6	-0.68	-0.67	-0.62	0.36	-0.4	0.37	-0.78	0.18	-0.61	0.06		0.05	-0.73	-0.8	-0.63	0.67	-0.6	-0.01	0.78	-0.56
Long Term Investments	-0.27	-0.15	0.0	0.23	-0.3	-0.36	-0.3	-0.43	-0.3	0.3	-0.45	-0.19	-0.09	0.36	-0.2	-0.21	0.05		-0.22	-0.21	-0.08	0.03	-0.59	-0.07	-0.04	-0.34
Common Stock	0.92	0.94	0.58	-0.58	0.67	0.67	0.77	0.93	0.83	-0.32	0.33	0.02	0.89	-0.42	0.63	0.27	-0.73	-0.22		0.91	0.75	-0.8	0.61	0.34	-0.73	0.62
Capital Surpluse	0.85	0.79	0.7	-0.81	0.63	0.75	0.84	0.92	0.81	-0.47	0.23	-0.28	0.98	-0.39	0.78	0.32	-0.8	-0.21	0.91		0.9	-0.91	0.65	0.39	-0.85	0.75
Long Term Debt Total	0.76	0.61	0.83	-0.8	0.38	0.79	0.83	0.75	0.79	-0.67	-0.09	-0.42	0.87	-0.61	0.84	0.53	-0.63	-0.08	0.75	0.9		-0.83	0.38	0.6	-0.87	0.87
Short Long Term Debt	-0.8	-0.66	-0.72	0.81	-0.66	-0.7	-0.82	-0.8	-0.76	0.52	-0.02	0.36	-0.92	0.36	-0.78	-0.18	0.67	0.03	-0.8	-0.91	-0.83		-0.6	-0.31	0.87	-0.64
Cash And Equivalents	0.56	0.49	0.19	-0.59	0.54	0.47	0.56	0.79	0.49	-0.25	0.37	-0.02	0.64	-0.04	0.41	-0.11	-0.6	-0.59	0.61	0.65	0.38	-0.6		-0.1	-0.37	0.36
Net Invested Capital	0.54	0.42	0.65	-0.22	0.23	0.63	0.56	0.32	0.63	-0.37	-0.27	-0.06	0.32	-0.52	0.64	0.97	-0.01	-0.07	0.34	0.39	0.6	-0.31	-0.1		-0.41	0.67
Net Working Capital	-0.8	-0.55	-0.9	0.89	-0.34	-0.84	-0.89	-0.65	-0.83	0.7	-0.1	0.54	-0.82	0.56	-0.89	-0.3	0.78	-0.04	-0.73	-0.85	-0.87	0.87	-0.37	-0.41		-0.83
Capital Stock	0.76	0.45	0.86	-0.81	0.23	0.94	0.9	0.65	0.86	-0.84	0.08	-0.43	0.64	-0.78	0.91	0.66	-0.56	-0.34	0.62	0.75	0.87	-0.64	0.36	0.67	-0.83

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Evolent Health

Ebitda Over Time

Evolent Ebitda

Ebitda

48.7 Million

As of now, Evolent Health's EBITDA is increasing as compared to previous years.

According to the company disclosure, Evolent Health reported earnings before interest,tax, depreciation and amortization of 46.38 M. This is 94.71% lower than that of the Health Care Technology sector and significantly higher than that of the Health Care industry. The ebitda for all United States stocks is 98.81% higher than that of the company.

Evolent EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evolent Health's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Evolent Health could also be used in its relative valuation, which is a method of valuing Evolent Health by comparing valuation metrics of similar companies.

Evolent Health is currently under evaluation in ebitda category among its peers.

Evolent Health ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Evolent Health's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Evolent Health's managers, analysts, and investors.

Environmental

Governance

Social

Evolent Health Institutional Holders

Institutional Holdings refers to the ownership stake in Evolent Health that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Evolent Health's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Evolent Health's value.

		Shares
Granahan Investment Management Inc..	2024-06-30	3 M
State Street Corp	2024-06-30	2.7 M
Orbimed Advisors, Llc	2024-06-30	2.6 M
Geode Capital Management, Llc	2024-06-30	2.6 M
Blair William & Co	2024-06-30	2.6 M
Dimensional Fund Advisors, Inc.	2024-06-30	2.4 M
Bank Of New York Mellon Corp	2024-06-30	2 M
Bellevue Group Ag	2024-06-30	1.7 M
Hood River Capital Management Llc	2024-06-30	1.6 M
Wellington Management Company Llp	2024-06-30	11.2 M
Vanguard Group Inc	2024-06-30	11.1 M

Evolent Fundamentals

	Return On Equity	-0.0594
	Return On Asset	0.01
	Profit Margin	(0.03) %
	Operating Margin	0.01 %
	Current Valuation	3.23 B
	Shares Outstanding	116.29 M
	Shares Owned By Insiders	3.95 %
	Shares Owned By Institutions	96.05 %
	Number Of Shares Shorted	12.53 M
	Price To Earning	(13.88) X
	Price To Book	2.56 X
	Price To Sales	1.15 X
	Revenue	1.96 B
	Gross Profit	316.58 M
	EBITDA	46.38 M
	Net Income	(113.04 M)
	Cash And Equivalents	188.2 M
	Cash Per Share	1.57 X
	Total Debt	644.8 M
	Debt To Equity	0.56 %
	Current Ratio	1.03 X
	Book Value Per Share	9.19 X
	Cash Flow From Operations	142.58 M
	Short Ratio	8.06 X
	Earnings Per Share	(0.94) X
	Price To Earnings To Growth	(1.37) X
	Target Price	41.66
	Number Of Employees	4.7 K
	Beta	1.56
	Market Capitalization	2.7 B
	Total Asset	2.68 B
	Retained Earnings	(719.19 M)
	Working Capital	9.43 M
	Current Asset	184.46 M
	Current Liabilities	59.51 M
	Net Asset	2.68 B

About Evolent Health Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Evolent Health's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evolent Health using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evolent Health based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

MSFT	Microsoft
V	Visa Class A
MSFT	Microsoft
BAC	Bank of America
CRM	Salesforce

When determining whether Evolent Health offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evolent Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evolent Health Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evolent Health Stock:

How To Invest In Evolent

Details

Is Evolent Stock a good investment?

Details

What is Evolent Health's Net Worth?

Details

Largest Health Care Technology Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Evolent Health Piotroski F Score and Evolent Health Altman Z Score analysis.

For more detail on how to invest in Evolent Stock please use our How to Invest in Evolent Health guide.

You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evolent Health. If investors know Evolent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evolent Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.94)

Revenue Per Share

20.705

Quarterly Revenue Growth

0.379

Return On Assets

0.01

Return On Equity

(0.06)

The market value of Evolent Health is measured differently than its book value, which is the value of Evolent that is recorded on the company's balance sheet. Investors also form their own opinion of Evolent Health's value that differs from its market value or its book value, called intrinsic value, which is Evolent Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evolent Health's market value can be influenced by many factors that don't directly affect Evolent Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Evolent Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evolent Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evolent Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Evolent Health Stock EBITDA

Evolent Health Company EBITDA Analysis

EBITDA

Revenue

-

Basic Expenses

Current Evolent Health EBITDA

Evolent EBITDA Driver Correlations

Evolent Ebitda

Ebitda

48.7 Million

Evolent EBITDA Peer Comparison

Evolent Health ESG Sustainability

Evolent Health Institutional Holders

Evolent Fundamentals

About Evolent Health Fundamental Analysis

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY